Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

'Like Water': Pharma Avoids Much Scrutiny In Messy Presidential Debate

Executive Summary

Trump and Biden trade barbs in debate that included a suggestion by the president that coronavirus vaccine development delays are political and saw Biden questioned on whether he was contributing to vaccine hesitancy.

You may also be interested in...



VP Debate: Pence Tries Vaccine Hesitancy Jujutsu On Harris

‘Senator, please stop undermining confidence in a vaccine,’ Pence says when confronted with the accusation that the administration is politicizing the COVID vaccine development effort.

Coronavirus Update: Trump Tests Positive, US Pause Remains On AstraZeneca Vaccine

Meanwhile, seven former US FDA commissioners issue joint plea for trust in the scientific integrity of the agency.

Pharma Catches A Break As Democrats Stumble In Rollout Of Pricing Investigation

House Oversight Committee plans to grill more companies on pricing later this year, but rushed rollout of reports from a long-running investigation, combined with competing higher profile news events, seemed to dampen the blow of the latest drug pricing scrutiny. Democrats failed to offer any new, unified solutions for their grievances with industry, while Republicans largely rushed to pharma’s defense.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS143011

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel